Stocks and Investing Stocks and Investing
Tue, December 14, 2021
Mon, December 13, 2021
Sun, December 12, 2021
Fri, December 10, 2021
Thu, December 9, 2021
Wed, December 8, 2021

Salveen Richter Maintained (ACAD) at Hold with Increased Target to $28 on, Dec 8th, 2021


Published on 2024-10-27 18:55:00 - WOPRAI, Salveen Richter
  Print publication without navigation


Salveen Richter of Goldman Sachs, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Increased Target from $25 to $28 on, Dec 8th, 2021.

Salveen has made no other calls on ACAD in the last 4 months.



There are 6 other peers that have a rating on ACAD. Out of the 6 peers that are also analyzing ACAD, 4 agree with Salveen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Tuesday, December 7th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021
  • Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $28 on, Tuesday, December 7th, 2021
  • Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021


These are the ratings of the 2 analyists that currently disagree with Salveen


  • Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $39 on, Tuesday, December 7th, 2021
  • Yatin Suneja of "Guggenheim" Upgraded from Hold to Strong Buy and Held Target at $23 on, Monday, November 1st, 2021